Recent news reveals Full House star Dave Coulier is battling stage 3 lymphoma, drawing attention and concern from fans ...

In turn, primary care experts called for a PET scan, CT scan and biopsy. Results then showed he had a “very aggressive” form ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

研究团队还通过调整水凝胶的力学性质，使其接近天然淋巴组织的硬度。将来自扁桃体的免疫细胞和外周血单个核细胞（PBMC）加入水凝胶中培养，观察其在不同条件下的生发中心反应。结果显示，PBMC来源的类器官能更长时间维持生发中心B细胞（GC B ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.

Dave Coulier has been diagnosed with Stage 3 non-Hodgkin lymphoma. The Full House alum shared the news on TODAY on Wednesday, ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Actor Dave Coulier, 65, has been diagnosed with stage 3 non-Hodgkin lymphoma.Coulier, formerly of "Full House," revealed his ...

“Three days later, my doctors called me back and they said, ‘We wish we had better news for you, but you have non-Hodgkin's ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...